Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 48 of 69 entries
Sorted by: Best Match Show Resources per page
The past and present of serum aminotransferases and the future of liver injury biomarkers.

EXCLI journal

McGill MR.
PMID: 28337112
EXCLI J. 2016 Dec 15;15:817-828. doi: 10.17179/excli2016-800. eCollection 2016.

Laboratory testing is important in the diagnosis and monitoring of liver injury and disease. Current liver tests include plasma markers of injury (e.g. aminotransferases, γ-glutamyl transferase, and alkaline phosphatase), markers of function (e.g. prothrombin time, bilirubin), viral hepatitis serologies,...

Cite
McGill MR. The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI J. 2016;15:817-828doi: 10.17179/excli2016-800.
McGill, M. R. (2016). The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI journal, 15817-828. https://doi.org/10.17179/excli2016-800
McGill, Mitchell R. "The past and present of serum aminotransferases and the future of liver injury biomarkers." EXCLI journal vol. 15 (2016): 817-828. doi: https://doi.org/10.17179/excli2016-800
McGill MR. The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI J. 2016 Dec 15;15:817-828. doi: 10.17179/excli2016-800. eCollection 2016. PMID: 28337112; PMCID: PMC5318690.
Copy Download .nbib Format: NLM
Ethanolic leaves extract of Trianthema portulacastrum L. ameliorates aflatoxin B(1) induced hepatic damage in rats.

Indian journal of clinical biochemistry : IJCB

Sharmila Banu G, Kumar G, Murugesan AG.
PMID: 23105844
Indian J Clin Biochem. 2009 Jul;24(3):250-6. doi: 10.1007/s12291-009-0047-5. Epub 2009 Sep 16.

Aflatoxins are potent hepatotoxic and hepatocarcinogenic agents. Reactive oxygen species and consequent peroxidative damage caused by aflatoxin are considered to be the main mechanisms leading to hepatotoxicity. The present investigation aims at assessing the hepatoprotective effect of ethanolic leaves...

Cite
Sharmila Banu G, Kumar G, Murugesan AG. Ethanolic leaves extract of Trianthema portulacastrum L. ameliorates aflatoxin B(1) induced hepatic damage in rats. Indian J Clin Biochem. 2009;24(3):250-6doi: 10.1007/s12291-009-0047-5.
Sharmila Banu, G., Kumar, G., & Murugesan, A. G. (2009). Ethanolic leaves extract of Trianthema portulacastrum L. ameliorates aflatoxin B(1) induced hepatic damage in rats. Indian journal of clinical biochemistry : IJCB, 24(3), 250-6. https://doi.org/10.1007/s12291-009-0047-5
Sharmila Banu, G, et al. "Ethanolic leaves extract of Trianthema portulacastrum L. ameliorates aflatoxin B(1) induced hepatic damage in rats." Indian journal of clinical biochemistry : IJCB vol. 24,3 (2009): 250-6. doi: https://doi.org/10.1007/s12291-009-0047-5
Sharmila Banu G, Kumar G, Murugesan AG. Ethanolic leaves extract of Trianthema portulacastrum L. ameliorates aflatoxin B(1) induced hepatic damage in rats. Indian J Clin Biochem. 2009 Jul;24(3):250-6. doi: 10.1007/s12291-009-0047-5. Epub 2009 Sep 16. PMID: 23105844; PMCID: PMC3453304.
Copy Download .nbib Format: NLM
Red ginseng extract protects against carbon tetrachloride-induced liver fibrosis.

Journal of ginseng research

Ki SH, Yang JH, Ku SK, Kim SC, Kim YW, Cho IJ.
PMID: 23717156
J Ginseng Res. 2013 Mar;37(1):45-53. doi: 10.5142/jgr.2013.37.45.

Korean red ginseng, the processed root of Panax ginseng Meyer, has been frequently used for various therapeutic purposes in oriental medicine. The present study investigated the possible effect of Korean red ginseng extract (RGE) for the treatment of liver...

Cite
Ki SH, Yang JH, Ku SK, et al. Red ginseng extract protects against carbon tetrachloride-induced liver fibrosis. J Ginseng Res. 2013;37(1):45-53doi: 10.5142/jgr.2013.37.45.
Ki, S. H., Yang, J. H., Ku, S. K., Kim, S. C., Kim, Y. W., & Cho, I. J. (2013). Red ginseng extract protects against carbon tetrachloride-induced liver fibrosis. Journal of ginseng research, 37(1), 45-53. https://doi.org/10.5142/jgr.2013.37.45
Ki, Sung Hwan, et al. "Red ginseng extract protects against carbon tetrachloride-induced liver fibrosis." Journal of ginseng research vol. 37,1 (2013): 45-53. doi: https://doi.org/10.5142/jgr.2013.37.45
Ki SH, Yang JH, Ku SK, Kim SC, Kim YW, Cho IJ. Red ginseng extract protects against carbon tetrachloride-induced liver fibrosis. J Ginseng Res. 2013 Mar;37(1):45-53. doi: 10.5142/jgr.2013.37.45. PMID: 23717156; PMCID: PMC3659625.
Copy Download .nbib Format: NLM
Protection of CCl4-Induced Liver and Kidney Damage by Phenolic Compounds in Leaf Extracts of Cnestis ferruginea (de Candolle).

Pharmacognosy research

Rahmat AA, Dar FA, Choudhary IM.
PMID: 24497738
Pharmacognosy Res. 2014 Jan;6(1):19-28. doi: 10.4103/0974-8490.122913.

BACKGROUND: The chemoprevention of chemically-induced hepatotoxicity is a crucial means of minimizing susceptibility to hepatic carcinogenesis and plants remain a rich source of anti-hepatotoxicants with antioxidant properties.OBJECTIVE: The protective role of defatted-methanol (MECF) and ethyl acetate fractions (EF), obtained...

Cite
Rahmat AA, Dar FA, Choudhary IM. Protection of CCl4-Induced Liver and Kidney Damage by Phenolic Compounds in Leaf Extracts of Cnestis ferruginea (de Candolle). Pharmacognosy Res. 2014;6(1):19-28doi: 10.4103/0974-8490.122913.
Rahmat, A. A., Dar, F. A., & Choudhary, I. M. (2014). Protection of CCl4-Induced Liver and Kidney Damage by Phenolic Compounds in Leaf Extracts of Cnestis ferruginea (de Candolle). Pharmacognosy research, 6(1), 19-28. https://doi.org/10.4103/0974-8490.122913
Rahmat, Adisa A, et al. "Protection of CCl4-Induced Liver and Kidney Damage by Phenolic Compounds in Leaf Extracts of Cnestis ferruginea (de Candolle)." Pharmacognosy research vol. 6,1 (2014): 19-28. doi: https://doi.org/10.4103/0974-8490.122913
Rahmat AA, Dar FA, Choudhary IM. Protection of CCl4-Induced Liver and Kidney Damage by Phenolic Compounds in Leaf Extracts of Cnestis ferruginea (de Candolle). Pharmacognosy Res. 2014 Jan;6(1):19-28. doi: 10.4103/0974-8490.122913. PMID: 24497738; PMCID: PMC3897004.
Copy Download .nbib Format: NLM
Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan.

Hepatology research : the official journal of the Japan Society of Hepatology

Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Chayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y.
PMID: 20156295
Hepatol Res. 2010 Jan;40(1):1-7. doi: 10.1111/j.1872-034X.2009.00633.x.

In the 2008 guidelines for the treatment of patients with cirrhosis, who are infected with hepatitis B virus (HBV), the main goal is to normalize levels of alanine and aspartate aminotransferases by eliminating HBV or reducing viral loads. In...

Cite
Kumada H, Okanoue T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010;40(1):1-7doi: 10.1111/j.1872-034X.2009.00633.x.
Kumada, H., Okanoue, T., Onji, M., Moriwaki, H., Izumi, N., Tanaka, E., Chayama, K., Sakisaka, S., Takehara, T., Oketani, M., Suzuki, F., Toyota, J., Nomura, H., Yoshioka, K., Seike, M., Yotsuyanagi, H., Ueno, Y. (2010). Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatology research : the official journal of the Japan Society of Hepatology, 40(1), 1-7. https://doi.org/10.1111/j.1872-034X.2009.00633.x
Kumada, Hiromitsu, et al. "Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan." Hepatology research : the official journal of the Japan Society of Hepatology vol. 40,1 (2010): 1-7. doi: https://doi.org/10.1111/j.1872-034X.2009.00633.x
Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Chayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010 Jan;40(1):1-7. doi: 10.1111/j.1872-034X.2009.00633.x. PMID: 20156295.
Copy Download .nbib Format: NLM
Salivary and Serum Aspartate Aminotransferases and Alanine Aminotransferases in Insulin-Dependent Diabetes Mellitus and Normal Children: A Comparative Study.

Journal of International Society of Preventive & Community Dentistry

Vinod KS, Madathil LP, Shetty P, Kaur H, Patel M, Gouraha A.
PMID: 29911060
J Int Soc Prev Community Dent. 2018 May-Jun;8(3):229-234. doi: 10.4103/jispcd.JISPCD_60_18. Epub 2018 Apr 30.

AIMS AND OBJECTIVES: The aim of the study was to estimate and compare aspartate aminotransferases (AST) and alanine aminotransferases (ALT) levels in saliva and serum of insulin-dependent diabetes mellitus (IDDM) and normal children, and the objective was to evaluate...

Cite
Vinod KS, Madathil LP, Shetty P, et al. Salivary and Serum Aspartate Aminotransferases and Alanine Aminotransferases in Insulin-Dependent Diabetes Mellitus and Normal Children: A Comparative Study. J Int Soc Prev Community Dent. 2018;8(3):229-234doi: 10.4103/jispcd.JISPCD_60_18.
Vinod, K. S., Madathil, L. P., Shetty, P., Kaur, H., Patel, M., & Gouraha, A. (2018). Salivary and Serum Aspartate Aminotransferases and Alanine Aminotransferases in Insulin-Dependent Diabetes Mellitus and Normal Children: A Comparative Study. Journal of International Society of Preventive & Community Dentistry, 8(3), 229-234. https://doi.org/10.4103/jispcd.JISPCD_60_18
Vinod, K S, et al. "Salivary and Serum Aspartate Aminotransferases and Alanine Aminotransferases in Insulin-Dependent Diabetes Mellitus and Normal Children: A Comparative Study." Journal of International Society of Preventive & Community Dentistry vol. 8,3 (2018): 229-234. doi: https://doi.org/10.4103/jispcd.JISPCD_60_18
Vinod KS, Madathil LP, Shetty P, Kaur H, Patel M, Gouraha A. Salivary and Serum Aspartate Aminotransferases and Alanine Aminotransferases in Insulin-Dependent Diabetes Mellitus and Normal Children: A Comparative Study. J Int Soc Prev Community Dent. 2018 May-Jun;8(3):229-234. doi: 10.4103/jispcd.JISPCD_60_18. Epub 2018 Apr 30. PMID: 29911060; PMCID: PMC5985679.
Copy Download .nbib Format: NLM
Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan.

Pakistan journal of medical sciences

Tahir M, Bashir U, Hafeez J, Ghafoor R.
PMID: 31086539
Pak J Med Sci. 2019 Mar-Apr;35(2):495-499. doi: 10.12669/pjms.35.2.54.

BACKGROUND & OBJECTIVE: Cutaneous Leishmaniasis (CL) is endemic in Baluchistan and treated traditionally with Meglumine antimoniate. Miltefosine appears appealing therapy in cutaneous Leishmaniasis. Our objective was to evaluate safety and efficacy of Miltifossine in treatment of cutaneous Leishmaniasis.METHODS: This...

Cite
Tahir M, Bashir U, Hafeez J, et al. Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan. Pak J Med Sci. 2019;35(2):495-499doi: 10.12669/pjms.35.2.54.
Tahir, M., Bashir, U., Hafeez, J., & Ghafoor, R. (2019). Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan. Pakistan journal of medical sciences, 35(2), 495-499. https://doi.org/10.12669/pjms.35.2.54
Tahir, Moizza, et al. "Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan." Pakistan journal of medical sciences vol. 35,2 (2019): 495-499. doi: https://doi.org/10.12669/pjms.35.2.54
Tahir M, Bashir U, Hafeez J, Ghafoor R. Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan. Pak J Med Sci. 2019 Mar-Apr;35(2):495-499. doi: 10.12669/pjms.35.2.54. PMID: 31086539; PMCID: PMC6500830.
Copy Download .nbib Format: NLM
THE EFFECTS OF REALSIL (SILYBIN-PHOSPHOLIPID-VITAMIN E COMPLEX) ON LIVER ENZYMES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) OR NON-ALCOHOLIC STEATO-HEPATITIS (NASH): A SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS.

Acta endocrinologica (Bucharest, Romania : 2005)

Derakhshandeh-Rishehri SM, Heidari-Beni M, Eftekhari MH.
PMID: 33029240
Acta Endocrinol (Buchar). 2020 Apr-Jun;16(2):223-231. doi: 10.4183/aeb.2020.223.

BACKGROUND: The aim of the present study was to systematically review the effects of Realsil (silybin-phospholipid-vitamin E complex) on liver enzymes in patients with NAFLD or NASH.METHODS: We searched Web of Science, MEDLINE, Google Scholar, Cochrane Library, Science Direct,...

Cite
Derakhshandeh-Rishehri SM, Heidari-Beni M, Eftekhari MH. THE EFFECTS OF REALSIL (SILYBIN-PHOSPHOLIPID-VITAMIN E COMPLEX) ON LIVER ENZYMES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) OR NON-ALCOHOLIC STEATO-HEPATITIS (NASH): A SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS. Acta Endocrinol (Buchar). 2020;16(2):223-231doi: 10.4183/aeb.2020.223.
Derakhshandeh-Rishehri, S. M., Heidari-Beni, M., & Eftekhari, M. H. (2020). THE EFFECTS OF REALSIL (SILYBIN-PHOSPHOLIPID-VITAMIN E COMPLEX) ON LIVER ENZYMES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) OR NON-ALCOHOLIC STEATO-HEPATITIS (NASH): A SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS. Acta endocrinologica (Bucharest, Romania : 2005), 16(2), 223-231. https://doi.org/10.4183/aeb.2020.223
Derakhshandeh-Rishehri, S M, et al. "THE EFFECTS OF REALSIL (SILYBIN-PHOSPHOLIPID-VITAMIN E COMPLEX) ON LIVER ENZYMES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) OR NON-ALCOHOLIC STEATO-HEPATITIS (NASH): A SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS." Acta endocrinologica (Bucharest, Romania : 2005) vol. 16,2 (2020): 223-231. doi: https://doi.org/10.4183/aeb.2020.223
Derakhshandeh-Rishehri SM, Heidari-Beni M, Eftekhari MH. THE EFFECTS OF REALSIL (SILYBIN-PHOSPHOLIPID-VITAMIN E COMPLEX) ON LIVER ENZYMES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) OR NON-ALCOHOLIC STEATO-HEPATITIS (NASH): A SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS. Acta Endocrinol (Buchar). 2020 Apr-Jun;16(2):223-231. doi: 10.4183/aeb.2020.223. PMID: 33029240; PMCID: PMC7535884.
Copy Download .nbib Format: NLM
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF.

European journal of cancer (Oxford, England : 1990)

Zimmer L, Livingstone E, Krackhardt A, Schultz ES, Göppner D, Assaf C, Trebing D, Stelter K, Windemuth-Kieselbach C, Ugurel S, Schadendorf D.
PMID: 34655839
Eur J Cancer. 2021 Oct 13;158:72-84. doi: 10.1016/j.ejca.2021.09.011. Epub 2021 Oct 13.

BACKGROUND: Combination of immune checkpoint inhibitors and mitogen-activated protein kinase (MAPK) pathway inhibitors (MAPKi) has been proposed to enhance the durability of anti-tumour responses induced by MAPKi. Here, we present phase I safety results from an open-label, phase I/II...

Cite
Zimmer L, Livingstone E, Krackhardt A, et al. Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF. Eur J Cancer. 2021;158:72-84doi: 10.1016/j.ejca.2021.09.011.
Zimmer, L., Livingstone, E., Krackhardt, A., Schultz, E. S., Göppner, D., Assaf, C., Trebing, D., Stelter, K., Windemuth-Kieselbach, C., Ugurel, S., & Schadendorf, D. (2021). Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF. European journal of cancer (Oxford, England : 1990), 15872-84. https://doi.org/10.1016/j.ejca.2021.09.011
Zimmer, Lisa, et al. "Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF." European journal of cancer (Oxford, England : 1990) vol. 158 (2021): 72-84. doi: https://doi.org/10.1016/j.ejca.2021.09.011
Zimmer L, Livingstone E, Krackhardt A, Schultz ES, Göppner D, Assaf C, Trebing D, Stelter K, Windemuth-Kieselbach C, Ugurel S, Schadendorf D. Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF. Eur J Cancer. 2021 Oct 13;158:72-84. doi: 10.1016/j.ejca.2021.09.011. Epub 2021 Oct 13. PMID: 34655839.
Copy Download .nbib Format: NLM
Impact of Nonalcoholic Steatohepatitis on the Outcome of Patients Undergoing Roux-en-Y Gastric Bypass Surgery: a Propensity Score-Matched Analysis.

Obesity surgery

Abbassi Z, Orci L, Meyer J, Sgardello SD, Goossens N, Rubbia-Brandt L, Spahr L, Buchs NC, Mönig SP, Toso C, Hagen ME, Jung MK.
PMID: 34546514
Obes Surg. 2021 Sep 21; doi: 10.1007/s11695-021-05642-0. Epub 2021 Sep 21.

PURPOSE: It is currently unknown whether NASH (nonalcoholic steatohepatitis), as compared to simple steatosis, is associated with impaired postoperative weight loss and metabolic outcomes after RYGB surgery. To compare the effectiveness of Roux-en-Y gastric bypass (RYGB) on patients with...

Cite
Abbassi Z, Orci L, Meyer J, et al. Impact of Nonalcoholic Steatohepatitis on the Outcome of Patients Undergoing Roux-en-Y Gastric Bypass Surgery: a Propensity Score-Matched Analysis. Obes Surg. 2021;doi: 10.1007/s11695-021-05642-0.
Abbassi, Z., Orci, L., Meyer, J., Sgardello, S. D., Goossens, N., Rubbia-Brandt, L., Spahr, L., Buchs, N. C., Mönig, S. P., Toso, C., Hagen, M. E., & Jung, M. K. (2021). Impact of Nonalcoholic Steatohepatitis on the Outcome of Patients Undergoing Roux-en-Y Gastric Bypass Surgery: a Propensity Score-Matched Analysis. Obesity surgery, . https://doi.org/10.1007/s11695-021-05642-0
Abbassi, Ziad, et al. "Impact of Nonalcoholic Steatohepatitis on the Outcome of Patients Undergoing Roux-en-Y Gastric Bypass Surgery: a Propensity Score-Matched Analysis." Obesity surgery vol. (2021). doi: https://doi.org/10.1007/s11695-021-05642-0
Abbassi Z, Orci L, Meyer J, Sgardello SD, Goossens N, Rubbia-Brandt L, Spahr L, Buchs NC, Mönig SP, Toso C, Hagen ME, Jung MK. Impact of Nonalcoholic Steatohepatitis on the Outcome of Patients Undergoing Roux-en-Y Gastric Bypass Surgery: a Propensity Score-Matched Analysis. Obes Surg. 2021 Sep 21; doi: 10.1007/s11695-021-05642-0. Epub 2021 Sep 21. PMID: 34546514.
Copy Download .nbib Format: NLM
The effects of low carbohydrate diets on liver function tests in nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials.

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences

Haghighatdoost F, Salehi-Abargouei A, Surkan PJ, Azadbakht L.
PMID: 27904598
J Res Med Sci. 2016 Jul 29;21:53. doi: 10.4103/1735-1995.187269. eCollection 2016.

BACKGROUND: Although several observational and experimental studies have examined the effects of low carbohydrate diets (LCDs) on nonalcoholic fatty liver disease (NAFLD), there are considerable inconsistencies among studies. We summarized the effect of LCDs on liver function tests, including...

Cite
Haghighatdoost F, Salehi-Abargouei A, Surkan PJ, et al. The effects of low carbohydrate diets on liver function tests in nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. J Res Med Sci. 2016;21:53doi: 10.4103/1735-1995.187269.
Haghighatdoost, F., Salehi-Abargouei, A., Surkan, P. J., & Azadbakht, L. (2016). The effects of low carbohydrate diets on liver function tests in nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2153. https://doi.org/10.4103/1735-1995.187269
Haghighatdoost, Fahimeh, et al. "The effects of low carbohydrate diets on liver function tests in nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials." Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences vol. 21 (2016): 53. doi: https://doi.org/10.4103/1735-1995.187269
Haghighatdoost F, Salehi-Abargouei A, Surkan PJ, Azadbakht L. The effects of low carbohydrate diets on liver function tests in nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. J Res Med Sci. 2016 Jul 29;21:53. doi: 10.4103/1735-1995.187269. eCollection 2016. PMID: 27904598; PMCID: PMC5122212.
Copy Download .nbib Format: NLM
Correlation of biochemical profile at admission with severity and outcome of COVID-19.

Journal of community hospital internal medicine perspectives

Sadiq A, Khurram M, Malik J, Chaudhary NA, Khan MM, Yasmeen T, Bhatti HW.
PMID: 34804383
J Community Hosp Intern Med Perspect. 2021 Nov 15;11(6):740-746. doi: 10.1080/20009666.2021.1974161. eCollection 2021.

BACKGROUND: COVID-19 was detected in China in December 2019. The rapid dissemination and novelty of the disease resulted in an epidemic. This study aimed to identify biochemical parameters at admission that can be used to categorize severity and outcome...

Cite
Sadiq A, Khurram M, Malik J, et al. Correlation of biochemical profile at admission with severity and outcome of COVID-19. J Community Hosp Intern Med Perspect. 2021;11(6):740-746doi: 10.1080/20009666.2021.1974161.
Sadiq, A., Khurram, M., Malik, J., Chaudhary, N. A., Khan, M. M., Yasmeen, T., & Bhatti, H. W. (2021). Correlation of biochemical profile at admission with severity and outcome of COVID-19. Journal of community hospital internal medicine perspectives, 11(6), 740-746. https://doi.org/10.1080/20009666.2021.1974161
Sadiq, Abdullah, et al. "Correlation of biochemical profile at admission with severity and outcome of COVID-19." Journal of community hospital internal medicine perspectives vol. 11,6 (2021): 740-746. doi: https://doi.org/10.1080/20009666.2021.1974161
Sadiq A, Khurram M, Malik J, Chaudhary NA, Khan MM, Yasmeen T, Bhatti HW. Correlation of biochemical profile at admission with severity and outcome of COVID-19. J Community Hosp Intern Med Perspect. 2021 Nov 15;11(6):740-746. doi: 10.1080/20009666.2021.1974161. eCollection 2021. PMID: 34804383; PMCID: PMC8604495.
Copy Download .nbib Format: NLM
Showing 37 to 48 of 69 entries